SEC Filing Summary
Filing and period: Form 10-K filed by Manhattan Pharmaceuticals, Inc. for the fiscal year ended December 31, 2011. The filing’s historical financial statements reflect TG Therapeutics, Inc. as the accounting acquirer following the December 29, 2011 reverse acquisition. TG began operations in April 2011, so the results are not a full-year or directly comparable presentation for the combined company. The filing is not a standalone fourth-quarter report.
Business Context
The company is a development-stage biopharmaceutical business with no product sales. Its principal program is ublituximab (TGTX-1101), an anti-CD20 antibody being developed for B-cell disorders, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma. Other disclosed programs include AST-726 for vitamin B12 deficiency and AST-915 for essential tremor; development of a topical psoriasis product had been discontinued.
In the reverse acquisition, TG shareholders received the majority of the combined company’s voting interests. TG became a majority-owned subsidiary, and the filing states that TG is the accounting acquirer. The company’s name and trading symbol changed to TG Therapeutics and TGTX, respectively, in January 2012.
Financial Results and Position
| Metric | 2011 / December 31, 2011 |
|---|---|
| Revenue | $0; no product or other operating revenue reported |
| Research and development expense | $327,283, including a $297,000 noncash charge associated with stock issued for the ublituximab license option |
| General and administrative expense | $554,691, including $86,494 of noncash compensation |
| Operating loss | $881,974 |
| Net loss | $889,071 consolidated; $853,074 attributable to Manhattan Pharmaceuticals, after the noncontrolling-interest allocation |
| Cash used in operating activities | $86,577 |
| Cash and cash equivalents | $9,748,491 |
| Total assets / total liabilities | $15,907,258 / $6,271,056 |
| Notes payable | $4,884,444, net; additionally, $719,972 of interest payable is reported |
| Stockholders’ equity | $9,624,521; total equity including noncontrolling interest was $9,636,202 |
Operating cash use was limited in this newly operating accounting entity and should not be assumed to represent the expected cash needs of planned clinical development. No meaningful year-over-year comparison is provided for the TG accounting predecessor. The filing reports no product revenue or gross margin.
Material Changes, Financing and Outlook
- Ublituximab license: In January 2012, TG exercised its option and entered into an exclusive license for worldwide development and commercialization rights except in France and Belgium. LFB Group may receive up to approximately $31 million in clinical, regulatory and sales milestones, plus royalties. TG issued 7,368,000 shares to LFB. Manhattan agreed to contribute $15 million, net of applicable financing fees and expenses, to TG for development funding in exchange for 7,500,000 TG shares.
- Additional financing: The December 2011 private placement raised gross proceeds of approximately $11.1 million. Two subsequent closings in January and February 2012 raised a further $13.9 million gross through preferred stock and included warrants. Management estimated that cash, including subsequent closings, would fund anticipated operating requirements for approximately 24–30 months from December 31, 2011. This estimate depends on development plans and other assumptions.
- Clinical progress: A Phase I CLL study reported partial responses in 5 of 11 evaluable patients in Part 2 at month four; rapid, near-total blood B-cell depletion was reported in most patients. Reported adverse events included infusion reactions, neutropenia, fever and thrombocytopenia. These early results do not establish later-stage efficacy or regulatory approval.
- Development plans: The company estimated approximately $4 million to complete the then-current ublituximab phase by mid-2014, subject to funding and clinical uncertainties. AST-726’s future was under review, with options including ending development, continuing under the FDA-agreed special protocol assessment, or adopting an alternative plan. Management said a decision was expected in 6–12 months.
- Debt and subsequent events: The ICON note’s $677,778 principal balance and $61,941 current interest payable were reported at year-end; the note was in default after a balloon payment due January 31, 2012 was not made. The $200,000 Swiss Pharma note was paid in February 2012. The filing also describes a continuing Hedrin joint-venture arbitration, with the company holding a 13% interest; the company had been removed as a party, while the counterparty’s stated damages demand was approximately $20 million.
Risks, Contingencies and Unusual Items
- The company had no approved products or commercial revenue and expected continuing operating losses. Future development and the stated runway depend on financing; failure to raise funds could delay or curtail programs.
- Development, regulatory approval, manufacturing, market acceptance and reimbursement are uncertain. The company relies on third parties for clinical work and manufacturing and identified potential single-source supply and transgenic-manufacturing risks.
- Management concluded internal control over financial reporting was ineffective at year-end because the CFO performed all financial and accounting duties, creating a lack of segregation of duties. The company said it intended to hire accounting personnel in 2012. Disclosure controls were reported effective.
- Preferred stock carried a $20-per-share liquidation preference and was convertible into 500 common shares per preferred share, subject to sufficient authorized common shares. The financing also issued substantial warrants, creating potential dilution. The company said it planned to address authorized-share capacity through a charter amendment or reverse stock split.
- The filing describes related-party connections involving the placement agent and executive chairman, who had an ownership interest in the placement agent’s parent and an affiliation with Opus. Placement compensation included commissions, warrants and an expense allowance; a $150,000 advisory fee was also disclosed.
- The audited financial statements received an unqualified auditor’s opinion. The filing identifies no material pending legal proceeding involving the company, while separately describing the Hedrin arbitration involving its joint venture.
Most Important Facts to Verify
- Confirm the precise accounting scope and periods represented by the 2011 financial statements after the reverse acquisition; these figures are not a full-year comparable history for the combined company.
- Reconcile reported year-end cash and the 24–30-month runway estimate with the subsequent financing, the planned $15 million TG contribution, fees, and expected clinical spending.
- Review the ICON note default, any waivers or repayment arrangements, and the status of other debt and interest obligations.
- Assess the potential dilution and voting impact of preferred-stock conversions, outstanding warrants, the LFB conversion option, and the proposed authorized-share changes.
- Track clinical evidence and regulatory plans for ublituximab, including U.S. IND status, trial design, manufacturing comparability and the estimated development cost and timeline.
- Monitor remediation of the internal-control segregation-of-duties weakness and developments in the Hedrin arbitration.